A phase II trial of adjuvant chemotherapy with 5-FU liver perfusion chemotherapy via the portal vein followed by gemcitabine plus S-1 (F-GS therapy) for patients with resectable pancreatic cancer (CCOG-1001) - A phase II trial of adjuvant chemotherapy with 5-FU liver perfusion chemotherapy via the portal vein followed by gemcitabine plus S-1 (F-GS therapy) for patients with resectable pancreatic cancer

Chubu Clinical Oncology Group0 个研究点目标入组 45 人开始时间: 2010年6月17日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) serious intra- or postoperative complications 2) regular use of fenitoin, warfarin or frucitocin 3) systemic administration of other fluorouracil 4) intractable watery diarrhea 5) severe psychological disease 6) active infection 7) serious complications (bowel paralysis, bowel obstruction, uncontrollable diabetes mellitus, heart failure, renal failure, active peptic ulcer, deep venous thrombosis and so on) 8) serious myelosuppression 9) interstitial pneumonia or pulmonary fibrosis 10) radiotherapy to the chest 11) pleural effusion or ascites 12) active malignancy in other organ 13) allergic reaction for gemcitabine or S-1 14) chronic liver damage 15) impossible insertion of the catheter to the portal vein 16) pregnant or breast feeding 17) Patients judged inappropriate for the study by the physicians

发起方

Chubu Clinical Oncology Group